Nervous System Active Pharmaceutical Ingredients Market size was valued at USD 219.45 billion in 2024 and is expected to reach USD 403.68 billion by 2037, registering around 4.8% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of nervous system active pharmaceutical ingredients is assessed at USD 236.63 billion.
The reason behind the growth is impelled by the growing presence of chronic diseases across the globe. This as a result is increasing the demand for active pharmaceutical ingredients as they are largely used to treat both acute and chronic pain.
The nervous system gets affected by several chronic disorders which necessitates the use of nervous system active pharmaceutical ingredients to help patients in managing these conditions. Every year, 17 million death take place globally owing to chronic diseases.
The growing geriatric population is believed to fuel the market growth. The elderly population is more prone to several neurological diseases such as Alzheimer’s, and Parkinson’s disease, and the rising number of elderly populations across the globe is estimated to drive market growth. Nervous system APIs help in managing the symptoms of these disorders and also help in pain management resulting from other age-related diseases. According to estimates, the number of individuals in the world who are 60 or older will rise to over 2 billion by 2050.
Growth Drivers
Challenges
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
4.8% |
|
Base Year Market Size (2024) |
USD 219.45 billion |
|
Forecast Year Market Size (2037) |
USD 403.68 billion |
|
Regional Scope |
|
Application (Diabetes, CVDs, Oncology, Neurological Disorder)
The CVDs segment is estimated to gain a robust market share in the coming years owing to the growing demand for nervous system APIs for effective treatments. Several nervous system active pharmaceutical systems are used to treat cardiovascular diseases, such as beta-blockers, and ACE inhibitors. Moreover, for the management of high blood pressure, ACE inhibitors and beta-blockers are utilized, and they are considered among the first-line treatment for heart failure and are highly successful in treating numerous cardiovascular illnesses. Moreover, in terms of decreasing blood pressure, (Angiotensin-converting enzymes) ACE inhibitors and beta-blockers are both equally effective since they can relax blood vessels in addition to reducing heart rate by blocking angiotensin-2.
Our in-depth analysis of the global market includes the following segments:
|
Product |
|
|
Application |
|
|
Expression System |
|
Asia Pacific industry is predicted to account for largest revenue share of 30% by 2037, impelled by the rising spending in healthcare. This, as a result, helps the pharmaceutical companies in the region to allocate more resources for the development of new nervous system active pharmaceutical ingredients to combat several neurological and cardiovascular diseases.
Besides this, rising investment in healthcare may also enable the development of novel drug delivery systems in the region for neurological diseases which necessitates the usage of nervous system APIs. According to data, the US spends the most on healthcare, and in 2021, health expenditures in the United States rose by more than 2%.
APAC Market Statistics
The Asia Pacific nervous system active pharmaceutical ingredients market is estimated to be the second largest share of 30%, during the forecast timeframe led by low labor costs. For instance, owing to the availability of cheap labor in countries such as India and Indonesia results in increasing production capacity for nervous system active pharmaceutical ingredients which can lead to an increased demand for these APIs in both local and international markets.
Author Credits: Rajrani Baghel
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?